Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 56Precursor Cell Lymphoblastic Leukemia-Lymphoma 45Myelodysplastic Syndromes 41Leukemia, Lymphocytic, Chronic, B-Cell 30Lymphoma, Non-Hodgkin 27Multiple Myeloma 22Leukemia, Myelogenous, Chronic, BCR-ABL Positive 22Hodgkin Disease 20Leukemia 17Myeloproliferative Disorders 16Recurrence 15Melanoma 15Lymphoma, Follicular 15Leukemia, Biphenotypic, Acute 15Lymphoma, Mantle-Cell 14Lymphoma 14Leukemia, Myelomonocytic, Chronic 14Lymphoma, Large B-Cell, Diffuse 13Hematologic Neoplasms 13Burkitt Lymphoma 11Anemia, Refractory, with Excess of Blasts 11Lymphoma, B-Cell, Marginal Zone 10Lymphoma, B-Cell 10Primary Myelofibrosis 8Neoplasm, Residual 7Neoplasm Metastasis 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Neuroblastoma 6Neoplasms 6Graft vs Host Disease 6

Interventions

Cytarabine 3Injections 2Idarubicin 2Gemtuzumab 2Filgrastim 2Decitabine 2veliparib 1fludarabine phosphate 1aldesleukin 1Whole-Body Irradiation 1Temozolomide 1Peripheral Blood Stem Cell Transplantation 1Granulocyte Colony-Stimulating Factor 1Etoposide 1Daunorubicin 1CPX-351 1Busulfan 1Bone Marrow Transplantation 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myelomonocytic, Acute × fludarabine phosphate × 1 year × Clear all
NCT00801489 2026-03-30

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 2 Recruiting
270 enrolled
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡